FOSINOPRIL TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

FOSINOPRIL SODIUM

Inapatikana kutoka:

SANIS HEALTH INC

ATC kanuni:

C09AA09

INN (Jina la Kimataifa):

FOSINOPRIL

Kipimo:

20MG

Dawa fomu:

TABLET

Tungo:

FOSINOPRIL SODIUM 20MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

100

Dawa ya aina:

Prescription

Eneo la matibabu:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0122777002; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2016-12-07

Tabia za bidhaa

1
PRODUCT MONOGRAPH
FOSINOPRIL
FOSINOPRIL SODIUM TABLETS USP
10 AND 20 MG
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
SANIS HEALTH INC.
DATE OF REVISION:
1 PRESIDENTS CHOICE CIRCLE
December 06, 2016
BRAMPTON, ONTARIO
L6Y 5S5
CONTROL NO: 199372
2
PRODUCT
MONOGRAPH
FOSINOPRIL
Fosinopril Sodium Tablets USP
10 and 20 mg
THERAPEUTIC
CLASSIFICATION
Angiotensin Converting Enzyme Inhibitor
ACTION
AND
CLINICAL
PHARMACOLOGY
Fosinopril sodium is an angiotensin converting enzyme (ACE) inhibitor
which is used in the
treatment of mild to moderate essential hypertension and in the
management of symptomatic
congestive heart failure.
Following oral administration, fosinopril sodium, an ester prodrug, is
rapidly hydrolyzed to
fosinoprilat, its principal active metabolite.
ACE is a peptidyl dipeptidase that catalyzes the conversion of
angiotensin I to the vasoconstrictor
substance, angiotensin II. Angiotensin II also stimulates aldosterone
secretion by the adrenal
cortex. Inhibition of ACE activity leads to decreased levels of
angiotensin II thereby resulting in
decreased vasoconstriction and decreased aldosterone secretion. The
latter decrease may result
in a small increase in serum potassium. Decreased levels of
angiotensin II, and the
accompanying lack of negative feedback on renal renin secretion,
results in increases in plasma
renin activity.
ACE is identical to kininase II. Thus, fosinopril may interfere with
the degradation of bradykinin, a
potent peptide vasodilator. However, it is not known whether this
contributes to the therapeutic
effects of fosinopril.
While the mechanism through which fosinopril sodium lowers blood
pressure appears to result
primarily from suppression of the renin-angiotensin-aldosterone
system, fosinopril sodium has an
antihypertensive effect even in patients with low-renin hypertension.
The antihypertensive effect of angiotensin converting enzyme
inhibitors is generally lower in black
patients than in non-blacks.
PHARMACOKINETICS AND METABOLISM
Following oral administration, fosinopril (the prodrug) is